Cargando…

Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma

Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults and around half of the patients develop metastasis and die shortly after because of the lack of effective therapies for metastatic UM. Consequently, new therapeutic approaches to this disease are welcome. In this re...

Descripción completa

Detalles Bibliográficos
Autores principales: Milán Rois, Paula, Latorre, Alfonso, Rodriguez Diaz, Ciro, del Moral, Álvaro, Somoza, Álvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352695/
https://www.ncbi.nlm.nih.gov/pubmed/31105250
http://dx.doi.org/10.3390/biomimetics3040028
_version_ 1783390898850103296
author Milán Rois, Paula
Latorre, Alfonso
Rodriguez Diaz, Ciro
del Moral, Álvaro
Somoza, Álvaro
author_facet Milán Rois, Paula
Latorre, Alfonso
Rodriguez Diaz, Ciro
del Moral, Álvaro
Somoza, Álvaro
author_sort Milán Rois, Paula
collection PubMed
description Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults and around half of the patients develop metastasis and die shortly after because of the lack of effective therapies for metastatic UM. Consequently, new therapeutic approaches to this disease are welcome. In this regard, microRNAs have been shown to have a key role in neoplasia progression and have the potential to be used as therapeutic tools. In addition, in different cancers including UM, a particular microRNA signature appears that is different from healthy cells. Thus, restoring the regular levels of microRNAs could restore the normal behavior of cells. In this study, four microRNAs downregulated in UM have been chosen to reprogram cancer cells, to promote cell death or increase their sensitivity to the chemotherapeutic SN38. Furthermore, to improve the internalization, stability and/or solubility of the therapeutic molecules employed in this approach, gold nanoparticles (AuNPs) were used as carriers. Remarkably, this study found a synergistic effect when the four oligonucleotides were employed and when the chemotherapeutic drug was added.
format Online
Article
Text
id pubmed-6352695
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63526952019-05-16 Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma Milán Rois, Paula Latorre, Alfonso Rodriguez Diaz, Ciro del Moral, Álvaro Somoza, Álvaro Biomimetics (Basel) Article Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults and around half of the patients develop metastasis and die shortly after because of the lack of effective therapies for metastatic UM. Consequently, new therapeutic approaches to this disease are welcome. In this regard, microRNAs have been shown to have a key role in neoplasia progression and have the potential to be used as therapeutic tools. In addition, in different cancers including UM, a particular microRNA signature appears that is different from healthy cells. Thus, restoring the regular levels of microRNAs could restore the normal behavior of cells. In this study, four microRNAs downregulated in UM have been chosen to reprogram cancer cells, to promote cell death or increase their sensitivity to the chemotherapeutic SN38. Furthermore, to improve the internalization, stability and/or solubility of the therapeutic molecules employed in this approach, gold nanoparticles (AuNPs) were used as carriers. Remarkably, this study found a synergistic effect when the four oligonucleotides were employed and when the chemotherapeutic drug was added. MDPI 2018-09-25 /pmc/articles/PMC6352695/ /pubmed/31105250 http://dx.doi.org/10.3390/biomimetics3040028 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Milán Rois, Paula
Latorre, Alfonso
Rodriguez Diaz, Ciro
del Moral, Álvaro
Somoza, Álvaro
Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma
title Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma
title_full Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma
title_fullStr Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma
title_full_unstemmed Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma
title_short Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma
title_sort reprogramming cells for synergistic combination therapy with nanotherapeutics against uveal melanoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352695/
https://www.ncbi.nlm.nih.gov/pubmed/31105250
http://dx.doi.org/10.3390/biomimetics3040028
work_keys_str_mv AT milanroispaula reprogrammingcellsforsynergisticcombinationtherapywithnanotherapeuticsagainstuvealmelanoma
AT latorrealfonso reprogrammingcellsforsynergisticcombinationtherapywithnanotherapeuticsagainstuvealmelanoma
AT rodriguezdiazciro reprogrammingcellsforsynergisticcombinationtherapywithnanotherapeuticsagainstuvealmelanoma
AT delmoralalvaro reprogrammingcellsforsynergisticcombinationtherapywithnanotherapeuticsagainstuvealmelanoma
AT somozaalvaro reprogrammingcellsforsynergisticcombinationtherapywithnanotherapeuticsagainstuvealmelanoma